Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

BACKGROUND: To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). METHODS: SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-resection,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pestalozzi, Bernhard C., Tausch, Christoph, Dedes, Konstantin J., Rochlitz, Christoph, Zimmermann, Stefan, von Moos, Roger, Winterhalder, Ralph, Ruhstaller, Thomas, Mueller, Andreas, Buser, Katharina, Borner, Markus, Novak, Urban, Nussbaum, Catrina Uhlmann, Seifert, Bettina, Bigler, Martin, Bize, Vincent, Vilei, Simona Berardi, Rageth, Christoph, Aebi, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390385/
https://www.ncbi.nlm.nih.gov/pubmed/28407750
http://dx.doi.org/10.1186/s12885-017-3261-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390385/
https://www.ncbi.nlm.nih.gov/pubmed/28407750
http://dx.doi.org/10.1186/s12885-017-3261-1

Ejemplares similares